Influenza Vaccine Production in China

Partnership objectives

Production of influenza vaccine in China. 

Influenza vaccines have been providing good levels of protection for more than 50 years. Influenza vaccines have been providing good levels of protection for more than 50 years. Copyright Sanofi Pasteur

What are the health needs and challenges?

Influenza occurs annually, causing significant amount of disease and death, particularly in the elderly, young children and those with certain chronic conditions.

The most common symptoms of the disease are chills, fever, sore throat, muscle pains, severe headache, coughing, weakness/fatigue and general discomfort. Although it is often confused with other influenza-like illnesses, especially the common cold, influenza is a more severe disease than the common cold and is caused by a different type of virus. Influenza can cause mild to severe illness, and at times can lead to death.

Influenza vaccines have been providing good levels of protection for more than 50 years. However, influenza vaccine production is highly complex and involves a large number of steps.

Description of partnership activities and how they address needs and challenges

In 2007, Sanofi Pasteur concluded an agreement with the Chinese Government, to build a facility to manufacture seasonal and pandemic influenza vaccines in Shenzhen, where Sanofi Pasteur already operates a facility. Sanofi Pasteur started the construction of the new vaccine manufacturing facility in 2008. The facility is now operational and the first doses produced were commercialized during the 2014/2015 influenza season.

The facility is designed for easy expansion to keep pace with the anticipated growth of the Chinese vaccine market.

Partnership information

Company(ies) Sanofi

Partner(s) Chinese Ministry of Health

Type of Partner(s) Government

Therapeutic Focus Women and Children's Health, Vaccine-Preventable Diseases

Disease(s) Children's Health, Influenza

Program Type(s) Availability of Treatment - Technology Transfer - Manufacturing and Entrepreneurial Know-How, Health System Infrastructure - Development of Physical Infrastructure, Prevention Programs - Vaccines

Targeted Population(s) Children, Elderly

Region(s) East Asia & Pacific

Number of Countries 1

Country(ies) China

Start Date 2007

More information Sanofi Pasteur

Anticipated completion date Ongoing